Abstract
Melanoma is the deadliest form of skin cancer being responsible for 80% of skin cancer deaths. Furthermore, the incidence of metastatic melanoma has increased over the past three decades with a mortality rate that continues to rise faster than most of all other cancers. The last few years have witnessed an unparalleled change in treatment options for patients with metastatic melanoma by the development of new therapeutic strategies like targeted therapies and immunotherapies that highly improved the patient’s prognosis. Despite the paradigm- shifting success of these novel treatments, their effectiveness is still limited by intrinsic or acquired resistance. The objective of this review is to provide an overview of the new available treatment modalities, criteria to select patients who might benefit from a specific therapy, mechanisms of innate and acquired resistance to these treatments and to discuss strategies to overcome drug resistance.
Keywords: Melanoma, chemotherapy, drug resistance, immunotherapy, targeted-therapies, BRAF, MEK.
Current Pharmaceutical Design
Title:The Emerging Therapeutic Landscape of Advanced Melanoma
Volume: 24 Issue: 5
Author(s): Vanessa Henriques, Teresa Martins, Wolfgang Link and Bibiana I. Ferreira*
Affiliation:
- Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, room 1.12, 8005-139 Faro,Portugal
Keywords: Melanoma, chemotherapy, drug resistance, immunotherapy, targeted-therapies, BRAF, MEK.
Abstract: Melanoma is the deadliest form of skin cancer being responsible for 80% of skin cancer deaths. Furthermore, the incidence of metastatic melanoma has increased over the past three decades with a mortality rate that continues to rise faster than most of all other cancers. The last few years have witnessed an unparalleled change in treatment options for patients with metastatic melanoma by the development of new therapeutic strategies like targeted therapies and immunotherapies that highly improved the patient’s prognosis. Despite the paradigm- shifting success of these novel treatments, their effectiveness is still limited by intrinsic or acquired resistance. The objective of this review is to provide an overview of the new available treatment modalities, criteria to select patients who might benefit from a specific therapy, mechanisms of innate and acquired resistance to these treatments and to discuss strategies to overcome drug resistance.
Export Options
About this article
Cite this article as:
Henriques Vanessa, Martins Teresa, Link Wolfgang and Ferreira I. Bibiana*, The Emerging Therapeutic Landscape of Advanced Melanoma, Current Pharmaceutical Design 2018; 24 (5) . https://dx.doi.org/10.2174/1381612824666180125093357
DOI https://dx.doi.org/10.2174/1381612824666180125093357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
Current Drug Metabolism Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Occurrence, Functions and Biological Significance of Arginine-Rich Proteins
Current Protein & Peptide Science Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology
Anti-Cancer Agents in Medicinal Chemistry The Janus Face of Cathelicidin in Tumorigenesis
Current Medicinal Chemistry Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer?
Anti-Cancer Agents in Medicinal Chemistry Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Applications of Natural Compounds in the Photodynamic Therapy of Skin Cancer
Current Medicinal Chemistry Predictors and Clinical Implications of HPV Reservoire Districts for Genital Tract Disease
Current Pharmaceutical Design Current Status of Vitamin D Signaling and Its Therapeutic Applications
Current Topics in Medicinal Chemistry Axitinib in the Treatment of Head and Neck Malignancies
Current Clinical Pharmacology Bestatin as an Experimental Tool in Mammals
Current Drug Metabolism Advances in Targeting Insulin-like Growth Factor Signaling Pathway in Cancer Treatment
Current Pharmaceutical Design Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design ETS Proteins and MMPs: Partners in Invasion and Metastasis
Current Drug Targets